Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
991 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03022409 | A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC). | completed | Phase 1 | 21 | AstraZenecaINDUSTRY | 3 | Aug 10, 2021 | clinicaltrials |
| NCT02197247 | Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC | completed | Phase 1 | 41 | AstraZenecaINDUSTRY | 6 | Jul 12, 2021 | clinicaltrials |
| NCT03853551 | Osimertinib Study in Indian Patients | completed | Phase 4 | 60 | AstraZenecaINDUSTRY | 1 | Jun 3, 2021 | clinicaltrials |
| NCT02777658 | PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLC(PANORAMA) | completed | — | 169 | AstraZenecaINDUSTRY | 1 | May 27, 2021 | clinicaltrials |
| NCT01714726 | Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease. | completed | Phase 2 | 121 | AstraZenecaINDUSTRY | 9 | May 26, 2021 | clinicaltrials |
| NCT02574637 | Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease | terminated | Phase 2 | 29 | AstraZenecaINDUSTRY | 12 | May 26, 2021 | clinicaltrials |
| NCT03658213 | To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.(LARES) | withdrawn | Phase 3 | 0 | AstraZenecaINDUSTRY | 1 | May 10, 2021 | clinicaltrials |
| NCT03205176 | AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas | completed | Phase 1 | 49 | AstraZenecaINDUSTRY | 2 | May 6, 2021 | clinicaltrials |
| NCT02127710 | A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC) | completed | Phase 2 | 111 | AstraZenecaINDUSTRY | 4 | Apr 19, 2021 | clinicaltrials |
| NCT04712396 | A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body | completed | Phase 1 | 11 | AstraZenecaINDUSTRY | 1 | Apr 9, 2021 | clinicaltrials |
| NCT01938612 | A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours | completed | Phase 1 | 269 | AstraZenecaINDUSTRY | 3 | Mar 12, 2021 | clinicaltrials |
| NCT04052113 | Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer(YODO) | completed | — | 152 | AstraZenecaINDUSTRY | 1 | Mar 1, 2021 | clinicaltrials |
| NCT02369874 | Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer(EAGLE) | completed | Phase 3 | 736 | AstraZenecaINDUSTRY | 24 | Feb 10, 2021 | clinicaltrials |
| NCT04675021 | Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects | completed | Phase 1 | 8 | AstraZenecaINDUSTRY | 1 | Jan 26, 2021 | clinicaltrials |
| NCT04546347 | A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833 | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 1 | Jan 20, 2021 | clinicaltrials |
| NCT02228369 | Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer(BLOOM) | completed | Phase 1 | 108 | AstraZenecaINDUSTRY | 4 | Jan 5, 2021 | clinicaltrials |
| NCT04031898 | Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)(REFLECT) | completed | — | 896 | AstraZenecaINDUSTRY | 1 | Dec 23, 2020 | clinicaltrials |
| NCT03457220 | An Observational Study to Evaluate AZD9291 Treatment in Patients With T790M Positive Non-small Cell Lung Cancer | completed | — | 423 | AstraZenecaINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT03980821 | A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies | completed | Phase 1 | 10 | AstraZenecaINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT03203993 | China Ovarian Cancer BRCA Testing Study(CRONUS) | terminated | — | 29 | AstraZenecaINDUSTRY | 2 | Oct 14, 2020 | clinicaltrials |
| NCT03725475 | A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients(KINDLE) | completed | — | 3,111 | AstraZenecaINDUSTRY | 10 | Oct 5, 2020 | clinicaltrials |
| NCT03553108 | A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.(IVIVC) | completed | Phase 1 | 18 | AstraZenecaINDUSTRY | 1 | Oct 1, 2020 | clinicaltrials |
| NCT02207530 | Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 112 | AstraZenecaINDUSTRY | 14 | Sep 29, 2020 | clinicaltrials |
| NCT02319044 | Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 267 | AstraZenecaINDUSTRY | 15 | Sep 29, 2020 | clinicaltrials |
| NCT01544179 | A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone(IMPRESS) | completed | Phase 3 | 265 | AstraZenecaINDUSTRY | 11 | Sep 25, 2020 | clinicaltrials |
| NCT02777567 | KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)(KOREA) | completed | — | 315 | AstraZenecaINDUSTRY | 1 | Sep 10, 2020 | clinicaltrials |
| NCT02658214 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Aug 20, 2020 | clinicaltrials |
| NCT03082976 | Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region(PREDICT) | completed | — | 108 | AstraZenecaINDUSTRY | 1 | Jul 16, 2020 | clinicaltrials |
| NCT02984423 | FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study(FLABRA) | completed | — | 471 | AstraZenecaINDUSTRY | 6 | Jul 10, 2020 | clinicaltrials |
| NCT04179071 | A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine | completed | Phase 1 | 16 | AstraZenecaINDUSTRY | 1 | Jul 7, 2020 | clinicaltrials |
| NCT02321046 | An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer).(ORTUS) | completed | — | 26 | AstraZenecaINDUSTRY | 1 | Jun 29, 2020 | clinicaltrials |
| NCT03501615 | An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia(MOXE) | approved for marketing | — | — | AstraZenecaINDUSTRY | 0 | Jun 29, 2020 | clinicaltrials |
| NCT03562819 | Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).(CONCORDANCE) | completed | — | 268 | AstraZenecaINDUSTRY | 1 | Jun 5, 2020 | clinicaltrials |
| NCT01884285 | AZD8186 First Time In Patient Ascending Dose Study | completed | Phase 1 | 147 | AstraZenecaINDUSTRY | 4 | May 29, 2020 | clinicaltrials |
| NCT03078036 | International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study(BREAKOUT) | completed | — | 873 | AstraZenecaINDUSTRY | 15 | May 20, 2020 | clinicaltrials |
| NCT03761901 | Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium(REVEAL) | completed | — | 141 | AstraZenecaINDUSTRY | 1 | May 8, 2020 | clinicaltrials |
| NCT02579226 | A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors. | completed | Phase 1 | 72 | AstraZenecaINDUSTRY | 1 | May 1, 2020 | clinicaltrials |
| NCT03259633 | An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1 | approved for marketing | — | — | AstraZenecaINDUSTRY | 1 | May 1, 2020 | clinicaltrials |
| NCT04118842 | A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin | completed | Phase 1 | 40 | AstraZenecaINDUSTRY | 1 | Apr 3, 2020 | clinicaltrials |
| NCT00952588 | Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients(SPARK-AML1) | completed | Phase 2 / Phase 3 | 74 | AstraZenecaINDUSTRY | 9 | Feb 24, 2020 | clinicaltrials |
| NCT03258515 | A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers | completed | Phase 1 | 45 | AstraZenecaINDUSTRY | 1 | Feb 20, 2020 | clinicaltrials |
| NCT02529995 | Phase I, Study in Chinese NSCLC Patients(AURAChinaPK) | completed | Phase 1 | 31 | AstraZenecaINDUSTRY | 1 | Feb 11, 2020 | clinicaltrials |
| NCT03236974 | Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.(D6090C00002) | completed | Phase 1 | 49 | AstraZenecaINDUSTRY | 2 | Feb 6, 2020 | clinicaltrials |
| NCT04121910 | A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole | completed | Phase 1 | 16 | AstraZenecaINDUSTRY | 1 | Jan 23, 2020 | clinicaltrials |
| NCT00313170 | A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg(FINDER II) | completed | Phase 2 | 144 | AstraZenecaINDUSTRY | 8 | Jan 6, 2020 | clinicaltrials |
| NCT03471572 | Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India(BRCA) | completed | — | 240 | AstraZenecaINDUSTRY | 1 | Dec 18, 2019 | clinicaltrials |
| NCT00628251 | Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer(ICEBERG 3) | completed | Phase 2 | 97 | AstraZenecaINDUSTRY | 9 | Dec 5, 2019 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials